Xenetic Biosciences (XBIO) Shares Outstanding (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Shares Outstanding (Entity) came in at $2.3 million in Q1 2026, up 27.12% YoY from $1.8 million in Q1 2025, and up 34.8% on a QoQ basis from $1.7 million in Q4 2025.
Xenetic Biosciences (XBIO) Shares Outstanding (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Shares Outstanding (Entity) data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 27.12% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 27.12% YoY) and the FY2025 annual result came in at $1.7 million, down 5.7% from the prior year.
- Shares Outstanding (Entity) advanced to $2.3 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $2.3 million in Q1 2026 to a low of $1.3 million in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.8 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 63.48% — and 2025, when it slipped 5.7%.
- Tracing XBIO's Shares Outstanding (Entity) over 5 years: stood at $1.5 million in 2022, then climbed by 18.76% to $1.8 million in 2023, then changed by 0.0% to $1.8 million in 2024, then slipped by 5.7% to $1.7 million in 2025, then soared by 34.8% to $2.3 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $2.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 2.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.29 Mn |
| Mar 31, 2026 | 2.29 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 1.42 Mn |
| Sep 30, 2022 | 1.43 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | 1.02 Mn |